Syros Pharmaceuticals, Inc. - common stock (SYRS) News
Filter SYRS News Items
SYRS News Results
|Loading, please wait...|
SYRS News Highlights
- SYRS's 30 day story count now stands at 5.
- Over the past 23 days, the trend for SYRS's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
- DRUG and HR are the most mentioned tickers in articles about SYRS.
Latest SYRS News From Around the Web
Below are the latest news stories about Syros Pharmaceuticals Inc that investors may wish to consider to help them evaluate SYRS as an investment opportunity.
Good morning, trader!
The U.S. Food and Drug Administration granted orphan drug designation to Syros Pharmaceuticals' (NASDAQ:SYRS) tamibarotene to treat myelodysplastic syndrome (MDS). Tamibarotene is currently being evaluated in combination with azacitidine in a phase 3 trial, dubbed SELECT-MDS-1, to treat RARA-positive patients with newly diagnosed higher-risk MDS (HR-MDS). The FDA grants orphan status to...
CAMBRIDGE, Mass., February 02, 2022--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to tamibarotene for the treatment of myelodysplastic syndrome (MDS). Tamibarotene, an oral first-in-class selective retinoic acid receptor alpha (RARα) agonist, is currently being evaluated in combination with azacitidine in the SELECT-MDS-
Syros Announces Clinical Updates and 2022 Goals to Support its Advancement to a Fully Integrated Biopharmaceutical Company
CAMBRIDGE, Mass., January 10, 2022--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today provided an update on its clinical development programs and outlined its strategic priorities and upcoming expected milestones.
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Equities analysts predict that Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) will announce earnings per share (EPS) of ($0.44) for the current fiscal quarter, Zacks Investment Research reports. Five analysts have provided estimates for Syros Pharmaceuticals earnings, with estimates ranging from ($0.48) to ($0.38). Syros Pharmaceuticals reported earnings of ($0.61) per share in the same quarter last year, 
Analysts forecast that Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) will post earnings of ($0.44) per share for the current fiscal quarter, according to Zacks. Five analysts have made estimates for Syros Pharmaceuticals earnings, with the highest EPS estimate coming in at ($0.38) and the lowest estimate coming in at ($0.48). Syros Pharmaceuticals posted earnings per share of 
Syros Pharmaceuticals Inc. (NASDAQ:SYRS) concluded the trading at $3.55 on Friday, December 03 with a fall of -7.07% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $3.82 and 5Y monthly beta was reading 1.88. Considering stocks 52-week price range provides that Syros Pharmaceuticals Inc. (SYRS): Significant Improvements, Worth Being Considered Read More »
Good morning, investor!
Nuveen Asset Management LLC increased its holdings in shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) by 23.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 180,514 shares of the companys stock after purchasing an additional 33,901 shares during the